REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

NCT03515629 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: REGN2810/ipi
DRUG: REGN2810/chemo/ipi
DRUG: Pembrolizumab

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]